Марказий Осиё эндокринологик журнали Том 4 № 3 (2024)
MODERN METHODS OF OBESITY TREATMENT
Нажмутдинова Дилором Камариддиновна, Садикова Азизахон Собит кизи
Аннотация
Relevance: Obesity is a significant global health issue requiring effective treatment methods. This study evaluates the impact of liraglutide, a glucagon-like peptide-1 (GLP-1) agonist, on non-diabetic obese patients. Purpose: To assess the effects of liraglutide on weight loss and cardiometabolic parameters. Materials and Methods: The study involved 20 patients receiving liraglutide for 12 weeks. Key indicators included weight loss and changes in cardiometabolic parameters. Results: Liraglutide-treated patients showed a weight reduction of 5.8%, with fasting glucose decreasing by 8.4%. Triglycerides decreased by 12%, and systolic blood pressure dropped by 5 mm Hg. Conclusion: Liraglutide is an effective and safe drug for weight loss and improving cardiometabolic health.
ожирение, лираглутид, снижение массы тела, кардиометаболические показатели, агонист ГПП-1obesity, liraglutide, weight loss, cardiometabolic parameters, GLP-1 agonistсемизлик, лираглутид, вазн йўқотиш, кардиометаболик кўрсаткичлар, ГПП-1 агонисти.
Источник метаданных: OAI-PMH архив журнала · Sindex не хранит полный текст, а даёт ссылку на источник.